Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19197254 | Vaccines against Chlamydia sp. | May 2025 | March 2026 | Allow | 10 | 2 | 1 | Yes | No |
| 18654900 | PHARMACEUTICAL COMPOSITIONS COMPRISING TEIXOBACTIN | May 2024 | December 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18603127 | METHODS OF USING GLYCOPOLYSIALYLATED THERAPEUTIC PROTEINS | March 2024 | January 2026 | Abandon | 22 | 1 | 1 | No | No |
| 18436355 | SCAFFOLD PROTEINS | February 2024 | December 2024 | Allow | 10 | 0 | 1 | No | No |
| 18420397 | TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2A | January 2024 | May 2025 | Abandon | 16 | 1 | 1 | No | No |
| 18412585 | NOVEL PTH MIMETIC PEPTIDE BASED ON PROTEIN DOMAIN RECONSTRUCTION AND APPLICATION THEREOF | January 2024 | May 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18393925 | METHODS OF SCAR PREVENTION AND/OR TREATMENT | December 2023 | October 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18513575 | Method for Side Effect Reduction in the Use of Statins Via Physiologically Synthesized Glutathione | November 2023 | April 2025 | Abandon | 16 | 2 | 1 | No | No |
| 18505472 | WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAME | November 2023 | December 2024 | Abandon | 13 | 2 | 1 | Yes | No |
| 18497741 | CYSTINE KNOT SCAFFOLD PLATFORM | October 2023 | January 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18497081 | APELIN POLYPEPTIDES | October 2023 | February 2026 | Allow | 27 | 1 | 1 | Yes | No |
| 18497900 | PEPTIDE COMPOSITION AND RESPECTIVE USES | October 2023 | April 2025 | Allow | 18 | 2 | 1 | No | No |
| 18491530 | METHODS AND COMPOSITIONS FOR TREATING CD44+ CANCERS | October 2023 | July 2024 | Abandon | 9 | 0 | 1 | No | No |
| 18480170 | SYNTHETIC PEPTIDE COMPOUNDS AND METHODS OF USE | October 2023 | January 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18449039 | DOSAGE REGIME FOR APOLIPOPROTEIN FORMULATIONS | August 2023 | October 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18366653 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | August 2023 | March 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18228879 | METHODS OF TREATING METASTATIC CANCERS USING AXL DECOY RECEPTORS | August 2023 | December 2025 | Abandon | 29 | 2 | 1 | No | No |
| 18228099 | PHOSPHORYLCHOLINE-TUFTSIN CONJUGATE FOR TREATING OCULAR INFLAMMATION | July 2023 | September 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18356944 | Alkali-Tolerant Affinity Chromatography Ligands | July 2023 | January 2026 | Allow | 30 | 3 | 1 | Yes | No |
| 18352800 | IN VIVO SYNTHESIS OF ELASTIC FIBER | July 2023 | March 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18217834 | ELEVATED INTRACRANIAL PRESSURE TREATMENT | July 2023 | September 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18210179 | PEPTIDE DERIVED FROM PEP27 PEPTIDE AND USES THEREOF | June 2023 | August 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18334287 | PEPTIDE COMPOSITION AND RESPECTIVE USES | June 2023 | July 2024 | Allow | 14 | 2 | 1 | No | No |
| 18310188 | PEPTIDE MODULATORS OF THE INTERACTION BETWEEN HUMAN C-PEPTIDE AND HUMAN ELASTIN RECEPTOR FOR THERAPEUTIC USE | May 2023 | May 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18194372 | PEPTIDE COMPOSITION AND RESPECTIVE USES | March 2023 | June 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18015975 | POLYPEPTIDE FOR PREVENTING OR TREATING IDIOPATHIC PULMONARY FIBROSIS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | January 2023 | December 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 18151910 | ANTIVIRAL COMPOSITIONS AND METHODS | January 2023 | February 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18079604 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE | December 2022 | June 2024 | Allow | 18 | 2 | 1 | No | No |
| 18057065 | METHOD OF TREATING PRADER-WILLI SYNDROME | November 2022 | February 2026 | Abandon | 39 | 3 | 1 | No | No |
| 17926095 | METHODS AND COMPOSITIONS FOR TREATING SARS-COV-2 INFECTION USING PEPTIDE NUCLEIC ACID-BASED AGENTS | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17998862 | STAT3 INHIBITION FOR TREATMENT AND PREVENTION OF HUMAN CORONAVIRUS INFECTION | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17924905 | TREATMENT OF RESPIRATORY VIRAL INFECTIONS | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18048655 | NOVEL PROTEIN VARIANT AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASE USING THE SAME | October 2022 | May 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 17917618 | ANTI-OBESITY PEPTIDES AND USES THEREOF | October 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17933502 | POLYPEPTIDE EXPRESSED IN THE STRATUM CORNEUM AND USE THEREOF | September 2022 | September 2024 | Abandon | 23 | 3 | 0 | No | No |
| 17819280 | PDL2 COMPOUNDS | August 2022 | September 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17875872 | WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAME | July 2022 | November 2023 | Abandon | 16 | 1 | 1 | Yes | No |
| 17858877 | IN VIVO SYNTHESIS OF ELASTIC FIBER | July 2022 | July 2023 | Abandon | 13 | 0 | 1 | No | No |
| 17810776 | COMPOSITIONS AND METHODS FOR TRANSPORT ACROSS THE BLOOD BRAIN BARRIER | July 2022 | August 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17786669 | ANTI-HER2 POLYPEPTIDES DERIVATIVES AS NEW DIAGNOSTIC MOLECULAR PROBES | June 2022 | December 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17843595 | CYSTINE KNOT SCAFFOLD PLATFORM | June 2022 | November 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17839264 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | June 2022 | April 2024 | Abandon | 22 | 2 | 1 | No | No |
| 17782869 | PEPTIDES FOR REGULATING GLUCOSE | June 2022 | January 2026 | Abandon | 43 | 1 | 1 | No | No |
| 17782376 | COMPOSITIONS AND METHODS EXCLUDING OR WITH REDUCED GLUTAMINE FOR THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASSEMIAS | June 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17781185 | PARATHYROID HORMONE ATTENUATES LOW BACK PAIN AND OSTEOARTHRITIC PAIN | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17824641 | TGF-B AS A THERAPEUTIC TARGET FOR INTRACRANIAL ANEURYSM | May 2022 | May 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17748212 | TREATING ALZHEIMER'S DISEASE | May 2022 | December 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17748163 | METHODS AND COMPOSITIONS FOR INHIBITING ADAM10 BIOLOGICAL ACTIVITIES | May 2022 | November 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17737789 | POLYPEPTIDE AND USE THEREOF | May 2022 | September 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17734828 | PEPTIDE LIBRARY AND USE THEREOF | May 2022 | February 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17660209 | METASTASIS INHIBITING PROTEIN | April 2022 | December 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17769709 | METHODS FOR TREATING CANCER | April 2022 | March 2026 | Abandon | 47 | 1 | 1 | No | No |
| 17720422 | CD71 BINDING FIBRONECTIN TYPE III DOMAINS | April 2022 | March 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17713233 | Method for Producing Peptide Ace Inhibitors | April 2022 | January 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17713140 | PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS | April 2022 | January 2023 | Allow | 10 | 1 | 1 | Yes | No |
| 17693978 | COMPOSITIONS AND METHODS FOR TREATING MYOCARDIAL INFARCTION AND ISCHEMIA | March 2022 | April 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17640817 | ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF | March 2022 | December 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17640322 | ANTIVIRAL PEPTOID COMPOSITIONS | March 2022 | February 2026 | Allow | 48 | 2 | 1 | No | No |
| 17684616 | Composition for Collagen-Based Drink Mix | March 2022 | June 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17678565 | DAP12 CONSTRUCTS AND THEIR USE TO ENHANCE DC VACCINES AND IMMUNOTHERAPIES | February 2022 | January 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17675837 | Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic Hormone | February 2022 | May 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17636715 | APTAMER ASSEMBLIES FOR PROTEIN CROSSLINKING | February 2022 | August 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17673361 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | February 2022 | August 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17635039 | EXENATIDE ANALOG AND USE THEREOF | February 2022 | July 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17668744 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION | February 2022 | August 2024 | Abandon | 30 | 2 | 0 | Yes | No |
| 17634433 | THERAPEUTIC PEPTIDES | February 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17665524 | Method of treatment of degenerative diseases caused by membrane channel-forming peptides fragments | February 2022 | August 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17632512 | APPLICATION OF POLYPEPTIDE OR DERIVATIVE THEREOF | February 2022 | April 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17591151 | ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY INDUCED OCULAR DISORDERS | February 2022 | March 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17632193 | Premixed Ultra-Stable Single-Chain Insulin Analogue Formulations | February 2022 | August 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17631807 | METHOD FOR TREATING ALZHEIMER'S DISEASE BY REGULATING AMINO ACID LEVEL | January 2022 | July 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17588736 | NOVEL PEPTIDE DERIVED FROM PEP27 PEPTIDE AND USES THEREOF | January 2022 | September 2023 | Abandon | 20 | 2 | 1 | No | No |
| 17597940 | NOVEL THERAPEUTIC USE | January 2022 | July 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17587427 | BIFUNCTIONAL BLOOD BRAIN THERAPIES FOR INTERLEUKIN-1 RELATED DISEASES | January 2022 | March 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17627373 | COMPOSITIONS AND METHODS OF TREATMENT FOR BREAST CANCER INVOLVING A NOVEL CAPER?-MLL1 COMPLEX | January 2022 | April 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17557874 | USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONIN | December 2021 | July 2024 | Abandon | 31 | 1 | 2 | Yes | No |
| 17556730 | NEUROPROTECTIVE PEPTIDES | December 2021 | February 2025 | Allow | 38 | 3 | 1 | Yes | No |
| 17621178 | CELL-PERMEABLE PEPTIDE | December 2021 | May 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17554486 | USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONIN | December 2021 | December 2022 | Abandon | 12 | 2 | 0 | Yes | No |
| 17551904 | PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST AN AGENT SELECTED FROM MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYCLIC ACID AND PARACETAMOL | December 2021 | November 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17618951 | PHARMACEUTICAL COMPOSITIONS FOR GLUCAGON AND GLP-1 CO-AGONIST PEPTIDES | December 2021 | January 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17616918 | PLANT TREATMENT | December 2021 | February 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17615201 | BIOACTIVE PEPTIDES AND COMPOSITIONS COMPRISING THEM | November 2021 | June 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17613974 | COLLAGEN COMPOSITIONS AND USES THEREOF | November 2021 | March 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17612020 | CYCLODEXTRIN BASED INJECTABLE COFORMULATIONS OF SGLT2 INHIBITORS AND INCRETIN PEPTIDES | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17526776 | METHODS FOR TREATING ARTHRITIS USING SPL-108 PEPTIDE | November 2021 | January 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17522115 | ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT | November 2021 | June 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17521425 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | November 2021 | July 2023 | Allow | 21 | 1 | 0 | Yes | No |
| 17608216 | STABLE ALBUVIRTIDE COMPOSITIONS | November 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17517063 | ANTI-INFLAMMATORY NANOFIBERS | November 2021 | August 2024 | Allow | 34 | 3 | 1 | Yes | No |
| 17607765 | COMPOSITION FOR PREVENTION OR TREATMENT OF HAIR LOSS INCLUDING HAPLN1 | October 2021 | May 2024 | Allow | 30 | 2 | 1 | No | No |
| 17594259 | MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | October 2021 | October 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17491219 | NOVEL TUMOR-SPECIFIC POLYPEPTIDE AND USE THEREOF | September 2021 | September 2023 | Allow | 24 | 2 | 1 | Yes | No |
| 17440461 | PHOTOIMMUNOTHERAPY AND PHARMACEUTICAL AGENT USED THEREFOR | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17477458 | Leucine/Peptide Composition and Method of Formulation | September 2021 | April 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17438839 | NOVEL ANTIMICROBIAL PEPTIDE DERIVED FROM PSEUDIN-2 PEPTIDE AND USES THEREOF | September 2021 | April 2025 | Allow | 43 | 2 | 1 | No | No |
| 17396577 | Treating Inflammatory Lung Disease | August 2021 | January 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17428574 | METHODS OF USING GLYCOPOLYSIALYLATED THERAPEUTIC PROTEINS | August 2021 | March 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17393495 | ANTIMICROBIAL PEPTIDES AND COMPOSITIONS, METHODS, ARTICLES & KITS RELATING THERETO | August 2021 | March 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17428615 | AMYLOID PEPTIDE VARIANTS | August 2021 | September 2025 | Allow | 50 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DABKOWSKI, ERINNE R.
With a 44.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DABKOWSKI, ERINNE R works in Art Unit 1654 and has examined 409 patent applications in our dataset. With an allowance rate of 55.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner DABKOWSKI, ERINNE R's allowance rate of 55.3% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DABKOWSKI, ERINNE R receive 2.36 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DABKOWSKI, ERINNE R is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +66.6% benefit to allowance rate for applications examined by DABKOWSKI, ERINNE R. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.2% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 31.2% of cases where such amendments are filed. This entry rate is in the 45% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 43.8% of appeals filed. This is in the 10% percentile among all examiners. Of these withdrawals, 28.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 97.1% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 54% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.